H. Lundbeck A/S

Lundbeck will present complete results from the PACIFIC trial extension study showing bexicaserin achieved a median 59.3% reduction in countable motor seizure frequency over 52 weeks in patients with developmental and epileptic encephalopathies.

Lundbeck received orphan drug designation from both the FDA and EMA for Lu AG13909, a novel humanized monoclonal antibody targeting ACTH for congenital adrenal hyperplasia treatment.

H. Lundbeck A/S announced positive results from the SUNRISE phase III trial, demonstrating eptinezumab's efficacy in a predominantly Asian population with chronic migraine.

NervGen Pharma has appointed Dr. Randall Kaye as Chief Medical Advisor to guide the clinical and regulatory strategy for NVG-291, following positive topline results from the chronic cohort of their Phase 1b/2a spinal cord injury trial.

Lundbeck presented results from the AMULET phase II trial investigating amlenetug, a monoclonal antibody targeting α-synuclein, as a potential treatment for multiple system atrophy (MSA).

The global Multiple System Atrophy (MSA) market is experiencing significant growth driven by emerging alpha-synuclein targeting therapies and advanced diagnostic technologies including high-resolution MRI and biomarker identification.

Lundbeck has partnered with the Danish Centre for AI Innovation to utilize Denmark's flagship Gefion AI supercomputer for accelerating neurological and psychiatric drug discovery.

Lundbeck presented data on bexicaserin, a selective 5-HT2C receptor superagonist, at the AES Annual Meeting, highlighting its potential in treating Developmental and Epileptic Encephalopathies (DEEs).

The RESOLUTION trial demonstrated that Vyepti (eptinezumab) is effective for patients with chronic migraine and medication-overuse headache (MOH).

Longboard Pharmaceuticals has started a Phase 3 clinical trial, DEEp SEA, to assess bexicaserin in Dravet syndrome patients aged 2-65 years.